CDMO and biosimilars maker mAbxience will install a new ABEC 4,000 L CSR Single use bioreactor at one of its site.

mAbxience, a leading international biopharmaceutical company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals is set to continue its ambitious growth plans with the installation of a new 4000 L Single Use Biorector at it´s Genhelix site in Spain. The new reactor will ensure continuity of the current business strategy augmenting existing capacity to the company´s growing biosimilar portfolio as well as adding to the potential for future CDMO projects.

With this new acquisition installed, mAbxience Genhelix site becomes the largest single biologics manufacturing facility in Spain and the first in Europe with fully integrated single use technology, supplying a rapidly expanding global market and offering significantly increased biosimilar and CDMO manufacturing capacity to its worldwide commercial partners.

Fresenius Kabi acquired a majority stake in mAbxience, joining Insud Pharma as shareholders in 2022.

“mAbxience is the perfect example of how innovation, cutting-edge R&D and manufacturing platform technology is used to deliver high quality medicines to patients, provide cost-effective alternatives to healthcare systems and guarantee its sustainability. Today’s announcement is testament to the hard work of our people that have grown mAbxience from its inception to the leading business it is today”, stated Emmanuelle Lepine, mAbxience CEO.